Physician profile
Richard Huslig
NPI 1346215746
$3,826.76
in general payments reported to CMS, 2019-2025
46 companies · $543 in 2025
The $543 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,241 · 2020: $456 · 2022: $85.66 · 2023: $277 · 2024: $225 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $276.36 | 2019-2023 | Piqray, Kisqali |
| Genentech USA, INC. | $259.92 | 2019-2025 | Itovebi |
| Pfizer INC. | $225.54 | 2019-2025 | |
| Janssen Biotech, INC. | $221.42 | 2019-2025 | Rybrevant, Talvey, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $209.69 | 2019-2025 | Opdualag, Opdivo |
| Amgen INC. | $177.26 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $172.02 | 2019-2023 | Imbruvica |
| Abbvie INC. | $145.19 | 2019-2025 | |
| Daiichi Sankyo INC. | $139.79 | 2019-2023 | Enhertu |
| Merck Sharp & Dohme LLC | $138.15 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Celgene Corporation | $137.20 | 2019-2025 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $128.81 | 2023-2025 | |
| Puma Biotechnology, INC. | $125.84 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $113.52 | 2019-2025 | Calquence |
| Alexion Pharmaceuticals, INC. | $113.42 | 2019-2023 | Ultomiris |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Huslig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.